News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Molecular Partners AG Comments on Allergan Inc. (AGN)'s Progress in Phase IIa Retinal Disease Trial Using Anti-VEGF DARPinĀ®


4/5/2012 9:14:07 AM

ZURICH-SCHLIEREN, Switzerland--(BUSINESS WIRE)--Molecular Partners AG today commented on the recent progress with its anti-VEGF DARPin (AGN-150998/MP0112), which is being developed in partnership with Allergan for ocular indications. Allergan announced last week at their R&D day that the compound successfully completed phase IIa development. AGN-150998/MP0112 was shown to be safe and well tolerated, with no dose limiting toxicity, after a single administration. Further, preliminary efficacy results from this study suggest a dosing interval of up to 3 months. Based on these results, Allergan has initiated a double-masked Phase IIb study comparing two high doses of AGN-150998/MP0112 with Lucentis, the current standard of care.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES